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Human parainfluenza virus type 1 (HPIV1), a major cause of croup in infants and young children, accounts for 6% of
hospitalizations for pediatric respiratory tract disease. The antigenically related Sendai virus, referred to here as murine PIV1
(MPIV1), is being considered for use as a live-attenuated vaccine to protect against HPIV1 (J. L. Hurwitz, K. F. Soike, M. Y.,
Sangster, A. Portner, R. E. Sealy, D. H. Dawson, and C. Coleclough, 1997, Vaccine 15(5), 533–540) and also as a recombinant
vaccine vector expressing antigens to protect against viral disease in humans. However, in the 1950s MPIV1 was reported
to have been isolated from humans, suggesting that zoonotic transmission might have occurred. It is therefore important to
examine the ability of MPIV1 to replicate in nonhuman primates, i.e., surrogate hosts for humans. In the present study the
level of replication of MPIV1 and HPIV1 was compared in African green monkeys and chimpanzees. Surprisingly, MPIV1
replicated as efficiently as HPIV1 in the upper and lower respiratory tract of African green monkeys at doses of 104 and 106
and replicated only slightly less efficiently at both sites in chimpanzees. African green monkeys immunized with MPIV1 were
highly resistant to subsequent challenge with HPIV1 even though MPIV1 did not induce a detectable HPIV1-neutralizing
antibody response. The high level of replication of MPIV1 observed in the upper and lower respiratory tract of these primates
suggests that MPIV1 likely would require significant attenuation before it could be given to humans as a vaccine againstINTRODUCTION
Paramyxoviridae is a large family of viruses that in-
cludes human parainfluenza virus types 1, 2, 3, 4A, and
4B (HPIV1, HPIV2, HPIV3, HPIV4A, and HPIV4B, respec-
tively). Sendai virus (MPIV1), simian virus 5 (SV5), and
bovine PIV3 (BPIV3) are the animal counterparts of
HPIV1, HPIV2, and HPIV3, respectively. Human and ani-
mal PIV1s and PIV3s are classified together in the genus
Respirovirus, and the PIV2s and PIV4s are classified in
the genus Rubulavirus. The natural host of Sendai virus
has not been clearly identified, but the virus is referred to
here as murine PIV1 (MPIV1) because it infects mice
efficiently, causes disease, and spreads readily to unin-
fected animals. SV5 was originally recovered from mon-
key tissue, but appears to be a canine virus. HPIV1,
HPIV2, and HPIV3 cause severe lower respiratory tract
disease that can lead to hospitalization of infants and
young children (Chanock et al., 2001). In a study of
infants and children over a 20-year period, HPIV1, HPIV2,
1 To whom correspondence and reprint requests should be addressed153and HPIV3 were identified as etiologic agents responsi-
ble for 6.0, 3.2, and 11.5%, respectively, of hospitalizations
for respiratory tract disease (Murphy et al., 1988). Infec-
tion with parainfluenza viruses can also lead to otitis
media in children (Heikkinen et al., 1999). Thus, a vaccine
is needed to protect against these viruses.
HPIV1 and MPIV1 are very similar in their nucleotide
and amino acid sequences (Newman et al., 2002). The
major antigenic determinants, the F and HN glycopro-
teins, are 68 and 72% identical, respectively (Gorman et
al., 1990; Komada et al., 1992; Lyn et al., 1991). The
antigenic relatedness that exists between MPIV1 and
HPIV1 suggested that MPIV1 could be used as a Jenne-
rian vaccine to protect against HPIV1 (Hurwitz et al.,
1997). In the Jennerian approach to vaccine develop-
ment, immunization against a human virus is achieved
using an antigenically related animal virus that is atten-
uated due to a natural host range restriction. There are a
number of instances where an animal virus has been
shown to be attenuated in humans and protective
against a related human virus (Kapikian et al., 1992;
Karron et al., 1995; Murphy and Chanock, 2001).
Pertinent to the parainfluenza viruses, BPIV3 is aHPIV1 or as a vaccine vector. Its ability to efficiently replica
host range restriction in primates and could theoretically c
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BPIV3, which is very similar to HPIV3 with regard to
genome organization and shares extensive sequence
and antigenic relatedness (Bailly et al., 2000), is re-
stricted in replication in the respiratory tract of rhesus
monkeys and chimpanzees (Clements et al., 1991;
Coelingh et al., 1988) as well as in seronegative human
infants and children (Karron et al., 1995). Despite its
reduced level of replication in the respiratory tract of
primates, BPIV3 is immunogenic and protective against
challenge with HPIV3 and is currently being further eval-
uated in clinical trials for use as a vaccine to protect
against HPIV3 (Karron et al., 1995; Lee et al., 2001).
With regard to PIV1, mice immunized with HPIV1 were
partially protected against a lethal dose of MPIV1 (Sang-
ster et al., 1995) and, similarly, African green monkeys
immunized with MPIV1 were protected against replica-
tion of HPIV1 following experimental challenge (Hurwitz
et al., 1997). However, in this previous study only the
upper respiratory tract was sampled for MPIV1 replica-
tion, and the replication of HPIV1 was not examined in
parallel to evaluate the expectation that MPIV1 was at-
tenuated in the primate host. Since a comparison of the
level of replication of MPIV1 and HPIV1 in the upper and
lower respiratory tract of primates has not been under-
taken and since MPIV1 is also being evaluated as a
vaccine vector to protect against human viral pathogens
(Matano et al., 2001), it was essential to determine
whether MPIV1 is satisfactorily attenuated in primates.
The issue of how well MPIV1 replicates in primates
also is of interest for reasons of epidemiology and nat-
ural history. Specifically, MPIV1 was reported to have
been isolated from infants in the early 1950s (Kuroya and
Ishida, 1953). However, during the ensuing years there
have been no further outbreaks of human disease. It has
thus remained unclear whether MPIV1 indeed had
caused disease and had been isolated from these young
children, perhaps as a consequence of zoonotic spread
from an animal reservoir, or whether the clinical samples
were contaminated with MPIV1 in the laboratory.
To assess the ability of MPIV1 to replicate in nonhu-
man primates, which serve as surrogates for humans,
the replication of MPIV1 was directly compared with that
of HPIV1 in the upper and lower respiratory tract of
seronegative African green monkeys and chimpanzees.
Both of these experimental animals have been shown
previously to support moderate levels of HPIV1 replica-
tion and are among the most permissive animal models
for evaluating candidate HPIV vaccines (Durbin et al.,
2000). Unexpectedly, our findings indicate that MPIV1 is
not significantly restricted in its replication in these pri-
mates compared to HPIV1. The implications of this ob-
servation for the use of MPIV1 as a Jennerian vaccine
and as a vector and for its putative association with
disease in humans are discussed.
RESULTS
HPIV1 and MPIV1 replicate to a similar level in the
upper and lower respiratory tract of African green
monkeys
Previously it was determined that seronegative African
green monkeys (Cercopithecus aethiops) and chimpan-
zees (Pan troglodytes) are suitable primate models in
which to evaluate the replication of HPIV1 (Durbin et al.,
2000), although it should be noted that these animals do
not develop HPIV1 disease and are therefore thought to
be less permissive than humans. To determine the rela-
tive level of replication, immunogenicity and protective
efficacy MPIV1, derived from a cDNA of the Sendai virus
Z strain, or HPIV1, a virulent wild-type (wt) virus (Murphy
et al., 1975), was administered to a group of four African
green monkeys, which were confirmed to be seronega-
tive for HPIV1. These animals were infected simulta-
neously by the intranasal (i.n.) and intratracheal (i.t.)
routes with 104 TCID50 of MPIV1 or HPIV1 in a 1 ml
inoculum at each site. Two additional groups of four
animals each were immunized in the same way with 106
TCID50 of MPIV1 or HPIV1 per site. The quantity of virus
in nasopharyngeal swab and tracheal lavage samples
was determined by limiting dilution assay on LLC-MK2
monolayers incubated at 32°C and is expressed as log10
TCID50/ml. The mean daily virus titer of nasal swab and
tracheal lavage samples throughout the course of the
study are presented in Fig. 1, and the mean peak virus
titers are shown in Table 1.
MPIV1 replicated to a similar level as HPIV1 in both
the upper and the lower respiratory tract of monkeys
infected with either 104 TCID50 or 10
6 TCID50. Specifically,
the two viruses were very similar with regard to the
duration and pattern of shedding at the two sites (Fig. 1,
Table 1) and also were very similar at each site on the
basis of the mean peak titer of the individual animals in
each group (Table 1). Thus, over a 100-fold range of virus
titer administered to the African green monkeys, MPIV1
was not attenuated for replication compared to HPIV1.
Illness was not observed in monkeys that were infected
with either MPIV1 or HPIV1.
Infection of African green monkeys with MPIV1
protected the monkeys from challenge with HPIV1
In the experiment described above, serum samples
were taken from the monkeys on day 0 immediately prior
to infection and on day 28. The African green monkeys
infected with HPIV1 or MPIV1 developed a high titer of
homologous serum hemagglutination inhibition (HAI) an-
tibodies (Table 1) and virus-neutralizing antibodies (data
not shown). However, the serum antibodies raised
against each virus did not cross-react efficiently with the
other (Table 1 and data not shown). In contrast, hamsters
infected with Sendai virus induced neutralizing antibody
to HPIV1, but not vice versa (Cook and Chanock, 1963).
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On day 28 postinfection, the animals described above
were challenged i.n. and i.t. with 106 TCID50 of wt HPIV1
per site, and the titer of virus in the nasopharyngeal
swab and tracheal lavage samples was determined as
described above. Shedding of the HPIV1 challenge virus
was not detected in the upper or lower respiratory tract
of animals that were previously infected with HPIV1,
whereas a very low level of HPIV1 shedding was de-
tected at both sites in animals that had been infected
with MPIV1 (Table 1).
MPIV1 replicates similar to HPIV1 in the upper and
lower respiratory tract of chimpanzees
To determine the relative level of replication and im-
munogenicity of MPIV1 and HPIV1 in chimpanzees, ani-
mals seronegative for HPIV1 were inoculated i.n. and i.t.
in groups of 2 with 105 TCID50 of MPIV1 or HPIV1. Naso-
pharyngeal swab and tracheal lavage samples were
collected as described for the African green monkeys,
and virus present in the samples was titered on LLC-
MK2 monolayers. As shown in Fig. 2, the duration and
pattern of shedding of MPIV1 and HPIV1 in the upper and
lower respiratory tract were similar, although on most
days the mean titer of MPIV1 was somewhat less than
that of HPIV1. However, the mean peak virus titer of the
individual animals in each group was similar (Table 2).
The small difference in virus shedding between MPIV1
and HPIV1 in the upper and lower respiratory tract of the
chimpanzee (Fig. 2) is reminiscent of the difference ob-
served between the RSV antigenic subgroups A and B in
the same experimental animal (Whitehead et al., 1999)
and represents only a marginal difference in replication
rather than a significant level of attenuation. Chimpan-
zees immunized with HPIV1 or MPIV1 developed a high
titer of homologous serum HAI antibodies (Table 2). With
the exception of one animal immunized with HPIV1,
which developed HAI antibodies to both HPIV1 (1:45) and
MPIV1 (1:11) (Table 2), the HAI responses were virus-
specific. Illness was not observed in chimpanzees that
were infected with either MPIV1 or HPIV1.
FIG. 1. The level of replication of MPIV1 and HPIV1 in the upper and lower respiratory tract of African green monkeys. Mean daily virus titers in
nasopharyngeal swab (A) or tracheal lavage (B) specimens obtained on the indicated day postinoculation from animals infected i.n. and i.t. with 104
(left) or 106 (right) TCID50 of the indicated virus: F, MPIV1 n  4; or E, HPIV1 n  4. Limit of detection  1.0 log10 TCID50/ml.
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DISCUSSION
Although MPIV1 was not satisfactorily attenuated for
nonhuman primates, it did provide a high level of protec-
tion against HPIV1 challenge, albeit one that was slightly
less protective than that induced by HPIV1. It was some-
what surprising that the high level of serum antibodies
induced by MPIV1 lacked detectable HAI or neutralizing
activity against HPIV1. The extent of amino acid se-
quence relatedness between MPIV1 vs HPIV1 in F and
HN (68 and 72%, respectively) is only marginally lower
than that between BPIV3 vs HPIV3 (79 and 75%, respec-
tively). However, BPIV3, but not MPIV1, induces antibod-
ies that efficiently neutralize its homologous HPIV. None-
theless, immunization of animals with MPIV1 induced a
high level of resistance to HPIV1 challenge. We suggest
that this protection was mediated by cellular immunity.
The greater protective efficacy of HPIV1 compared to
MPIV1 against HPIV1 challenge likely reflects the com-
bined contribution of cellular immunity and neutralizing
antibodies. Cellular immunity is known to play a role in
combating PIV1 infections (Hou et al., 1992; Tao et al.,
1999).
Although Sendai virus is often referred to as MPIV1,
this species designation is based on its permissiveness
during laboratory infection rather than evidence from
nature. Indeed, there is a lack of virologic or serological
evidence of MPIV1 in wild mouse populations (Ishida
and Homma, 1978), and the natural host or hosts of
MPIV1 remain unknown. There are two known lineages
of MPIV1 (Fujii et al., 2001; Itoh et al., 1997; Sakaguchi et
al., 1994; Wang et al., 1994). The MPIV1 used in the
present study is a recombinant virus derived from the Z
strain of MPIV1 (Garcin et al., 1997) that was isolated in
the early 1950s, subsequent to an epidemic of pneumo-
nitis of newborn infants in Sendai, Japan (Ishida and
Homma, 1978; Kuroya and Ishida, 1953). The Z strain of
MPIV1 is highly related by nucleotide sequence analysis
(about 99% sequence identity) to the Harris (H) and
Fushimi strains, and thus these “strains” probably repre-
sent a single Z/H/Fushimi strain that has been passaged
extensively in eggs in various laboratories since the
1950s (Giorgi et al., 1983; Homann and Neubert, 1989;
Shioda et al., 1983). Z/H/Fushimi egg passage strains are
only moderately virulent for mice with a lethal dose50
(LD50) of about 10
4 PFU.
The second lineage consists of two highly virulent, low
egg-passage viruses (LD50  10
2), the Ohita M and
Hamanatsu strains, which were isolated in Japan from
separate severe epidemics in laboratory mice in sepa-
rate locations (Itoh et al., 1992; Kiyotani et al., 1990).
Passage of the Hamanatsu strain in eggs readily atten-
uates the virus for mice such that the virulence of the
egg-passaged Hamanatsu strain resembles that of the
Z/H/Fushimi strain, indicating that adaptation to replica-
tion in eggs attenuates the virus for mice (Kiyotani et al.,
2001). Both the highly virulent Ohita M and Hamanatsu
strains have now been sequenced, and they are 99.2%
identical to each other, and 89% identical to the Z/H/
Fushimi strains (Fujii et al., 2001; Itoh et al., 1997).
Here we report that a recombinant version of the
egg-adapted Z strain of MPIV1 that is only moderately
virulent in laboratory mice replicates as efficiently as
HPIV1 in the monkey and chimpanzee models of human
respiratory infection. The observation that field strains of
TABLE 1






Response to immunization Response to challengeg
Mean peak virus titerb,c
(log10 TCID50/ml  S.E.)
Serum HAI antibody
titer (mean recip.
log2  SE) against




HPIV1 on day 28 f
Mean peak HPIV1 challenge
virus titerb (log10 TCID50/ml  S.E.)
NP swabd Tracheal lavagee NP swabh Tracheal lavageh
MPIV1 (104) 4 5.7 0.2 5.4 0.5 9.0 0.7 1.0 0.0 1.6 0.7 1.9 0.7
HPIV1 (104) 4 4.9 0.4 4.7 0.3 1.0 0.0 7.5 0.3 0.5 0.0 0.5 0.0
MPIV1 (106) 4 4.9 0.3 6.9 0.2 9.8 0.7 1.0 0.0 1.4 0.4 1.6 0.8
HPIV1 (106) 4 5.6 0.3 6.0 0.5 1.0 0.0 8.3 0.3 0.5 0.0 0.5 0.0
a Monkeys were inoculated intranasally and intratracheally with indicated amount of virus in a 1-ml inoculum at each site.
b Mean of the peak virus titers for the animals in each group irrespective of sampling day. SE, standard error.
c Virus titrations were performed on LLC-MK2 cells at 32°C. The limit of detection was 1.0 log10 TCID50/ml.
d Nasopharyngeal swab samples were collected on days 1 to 10 and 14 postinfection. The titers on day 0 were 0.5 log10 TCID50/ml.
e Trachael lavage samples were collected on days 2, 4, 6, 8, 10, and 14 postinfection. The titers on day 0 were 0.5 log10 TCID50/ml.
f Serum HAI titer is expressed as the mean reciprocal log2  standard error. The titer on day 0 was 1.0.
g Animals were challenged with 6.0 log10 TCID50 of HPIV1 in a 1 ml inoculum i.n. and i.t.
h Nasopharyngeal swab and tracheal lavage samples were collected on days 0, 2, 4, 6, and 8 postchallenge. The titers on day 0 were 0.5 log10
TCID50/ml.
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MPIV1 are much more virulent in mice than the egg-
passaged recombinant Z strain tested here raises the
possibility that MPIV1 strains that are transmitted to
humans directly from a natural host might exhibit even
greater virulence in nonhuman primates than the egg-
adapted strain. Given these unexpected findings, and the
fact that some of the original patient isolates were known
not to have been passaged in mice (Ishida and Homma,
1978), field strains of this virus could well have been
responsible for the outbreak of fatal pneumonitis in new-
born infants in Sendai, Japan, in 1952.
The findings from the present study also indicate that
it would be risky to use wild-type MPIV1 as a Jennerian
vaccine for HPIV1. Essential characteristics for candidate
Jennerian vaccines are attenuation of replication, immu-
nogenicity, and protective efficacy against their human
counterparts. For example, BPIV3 had been previously
shown to be attenuated for replication in both the upper
and the lower respiratory tract of rhesus monkeys
(Coelingh et al., 1988) and in the lower respiratory tract of
chimpanzees (Clements et al., 1991). Therefore, before
studies were initiated in humans with BPIV3, an attenu-
ation phenotype had been demonstrated for two primate
species. The MPIV1 used in the present study was in-
deed immunogenic and protective against HPIV1 but,
unexpectedly, did not appear to be sufficiently attenuated
in the nonhuman primates tested. Based on the informa-
tion derived from the present study, it might be expected
FIG. 2. The level of replication of MPIV1 and HPIV1 in the upper and lower respiratory tract of chimpanzees. Mean daily virus titers in
nasopharyngeal swab (A) or tracheal lavage (B) specimens obtained on the indicated day postinoculation from animals infected i.n. and i.t. with 105
TCID50 of the indicated virus: F, MPIV1 n  2; or E, HPIV1 n  2. Limit of detection  1.0 log10 TCID50/ml.
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that MPIV1 would replicate to a high level in humans and
could, therefore, also cause disease. Similarly, use of
MPIV1 as a vector to immunize humans against addi-
tional pathogens may require attenuation of the MPIV1
vector. The suggestion that considerable caution should
be exercised before proceeding with an evaluation of
MPIV1 in humans is offered with the knowledge that
many nonhuman paramyxoviruses and myxoviruses, in-
cluding Menangle virus (Bowden et al., 2001; Chant et al.,
1998), Hendra virus (Murray et al., 1995; Selvey et al.,
1995), Nipah virus (Chua et al., 2000; Paton et al., 1999),
Newcastle Disease virus (Hanson and Brandly, 1958),
and avian influenza A viruses (Alexander and Brown,
2000; Subbarao and Katz, 2000), are fully capable of
causing disease in humans following interspecies trans-
fer. Thus, not all animal viruses can serve as “Jennerian”
vaccines, but rather only that subset that is restricted for
replication, or otherwise attenuated, in the human host.
MATERIALS AND METHODS
Cells and viruses
LLC-MK2 cells (ATCC CCL 7.1) were maintained in
OptiMEM I (Life Technologies, Gaithersburg, MD) sup-
plemented with 5% FBS and gentamicin sulfate (50 g/
mL), or in EMEM supplemented with 10% FBS, gentami-
cin sulfate (50 g/ml), and 2 mM glutamine. The biolog-
ically derived HPIV1/WASH/20993/1964 isolate used in
this work was confirmed previously to be virulent in
human volunteers (Murphy et al., 1975) and was propa-
gated in LLC-MK2 cells as described previously (Tao et
al., 1998). Recombinant wild-type Sendai virus, strain Z
(referred to here as MPIV1), was recovered from cDNA
as described previously (Garcin et al., 1997) and was
confirmed to be moderately virulent for mice (Garcin et
al., 1997). It was passaged once in LLC-MK2 cells in
OptiMEM I (Life Technologies) that was supplemented
with gentamicin sulfate (50 g/ml) and porcine-derived
trypsin (1.2 g/ml; BioWhitaker, MD).
Evaluation of viruses in African green monkeys and
chimpanzees
African green monkeys (C. aethiops) and chimpanzees
(P. troglodytes) that were negative for serum HAI anti-
body to HPIV1 were inoculated simultaneously by the i.n.
and i.t. routes with 1 ml per site of L15 medium contain-
ing 104 or 106 TCID50 of virus, as described previously
(Durbin et al., 2000). Nasopharyngeal (NP) swab samples
were collected on days 1 through 10 and 14 postinfec-
tion, and tracheal lavage (TL) samples were collected on
days 2, 4, 6, 8, 10, and 14 postinfection. Virus present in
the NP and TL specimens was quantified by titration on
LLC-MK2 cell monolayers at 32°C, as previously de-
scribed (Durbin et al., 2000), and the mean peak virus
titer obtained was expressed as log10 TCID50/ml.
African green monkeys were challenged i.n. and i.t.
with 106 TCID50 of wild-type HPIV1 28 days after immu-
nization, and NP and TL samples were collected on days
2, 4, 6, and 8 postchallenge. HPIV1 present in the sam-
ples was quantified as described above. The pre- and
postimmunization serum HAI or virus neutralizing anti-
body titer to HPIV1 or Sendai virus was measured as
described previously (Durbin et al., 2000; van Wyke
Coelingh et al., 1985).
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